In October 2014 the European Commission (EC) allocated €24.4 million of the European Union (EU) budget to urgently fund needs for Ebola Virus Disease (EVD) outbreak response and research. This funding has empowered the “EU research and innovation program (EURIP)”, through Horizon 2020, the necessary means to be operational in a short period of time and thus to actively participate in the response to the present EVD outbreak in West Africa. Through this initiative the EURIP has selected and rewarded five projects with scopes ranging from testing existing and novel compounds of interest for EVD treatment to large-scale clinical trials of a potential vaccine.
“The EC with the WHO bringing the international community together in Geneva, (stressed) one of the most important messages is that we need to step up medical research on Ebola" and "These projects enlist the best academic researchers and industry to take the fight to this deadly disease” Máire Geoghegan-Quinn, EU Innovation & Science Commissioner
"We're in a race against time on Ebola, and we must address both the emergency situation and at the same time have a long term response.” José Manuel Barroso, former President of the European Commission.
The IF-Ebola European action (project), one of the five EC funded projects, stands for “Innovative technologies to Fight Ebola” intends to strategically test a novel anti-Ebola compound in early-infected patients (EBOV contacts) as a MEURI, which stands for “Monitored Emergency use of Unregistered and Experimental clinical Intervention” in Sierra Leone and Guinea. Our philosophy can be summarized as follows: “An early passive anti-Ebola immunotherapy prompted by timely EVD-diagnosis, along with appropriate follow-up”.
Our proposal has been designed to efficiently respond to critical needs required by the local African public health authorities under the guidance of the WHO in order to ultimately support response efforts to control the current EVD outbreak.
The project will target main ongoing EVD epidemic areas of Sierra Leone and Guinea. The consortium includes companies and institutions (listed below), which will extend their support to public health authorities, health workers, and laboratory experts responding on site to the EVD outbreak. We thus have established a wide operational consortium of outstanding complementary partners, sharing innovative technological approaches towards a common goal. All phases of the study will be reviewed and implemented following Sierra Leone, Guinea and international ethical approvals and guidance.
Within this framework, our aim is to provide an innovative early treatment based on an accurate early diagnostic under a format of two successive phases:
As previously demonstrated for different pathogens or toxins, including rabies virus and H5N1 avian influenza virus, it is expected that this approach will positively impact the vital prognostic of early EVD-diagnosed and treated patients. The evolution of their homeostasis parameters will be followed during and after this treatment (once patients become convalescent). Altogether, it is expected to significantly reduce the overall mortality rate.
Moreover, the follow-up study of the homeostasis changes in patients will help us to generate high quality and unique scientific data to understand the EVD pathology observed in this exceptional outbreak. Thus, the therapeutic effects and cure parameters will be mainly followed-up by studying profiles of the: immune-response (Next Generation Sequencing, metagenomics); co-infections (DNA-arrays) including potential negative interactions (e.g.: concurrent malaria, Lassa, infectious respiratory or gastro enteritis syndromes); and, ebolavirus diversity (sequencing and metagenomics).
This program requires a high quality operational organization concurrently set up in partnership with in-country and international health authorities in connection with the members of our consortium who have longstanding experience of EVD outbreaks and that are already present on the ground in Africa.
The project will be set up in appropriate EVD treatment and holding centers in both Sierra Leone and Guinea. To maximize our productivity we seek an open collaboration with persons in charge of local and international institutions. Within the pre-identified sites, besides laboratory and clinical partnerships, we expect to access contact-tracing procedures in compliance with our ethically approved sampling methods to generate the high quality data necessary to assess the current clinical presentation to properly evaluate our early therapeutic intervention.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 666102 . This publication [communication] reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.
"A new era in Ebola diagnosis and treatment" article is online on the CORDIS website.To read the integrality of the article, follo...View more
Resveratrol formulated with a natural deep eutectic solvent inhibits active matrix metalloprotease-9 in hormetic conditions. Shamseddin...View more
RIGEL as a Powerful Computational Architecture for Genomic & Metagenomic Signature Discrimination: Analysis of the 2014-15 West African...View more
An article has been published in the European Journal of Lipid Science and Technology that can be downloaded from the Document section of th...View more
The IF Ebola new state of play is available and downloadable in the "Document" section
The European Commission announced €24.4 million from the EU budget for urgently needed Ebola research.
In Cali, Colombia
In Cali, Colombia
Recent history has demonstrated that both military and civilian populations could be exposed to highly hazardous chemical, biological, radiological, nuclear and explosive (CBRNE) agents following conflicts, natural outbreaks and disasters, industrial incidents or terrorist attacks.
Worldwide, research and industrial capacities have been engaged to provide answers adapted to these challenges. Building on the success of the 1st International Conference on CBRNE Research & Innovation (Antibes, 2015), this is an opportunity to build and strengthen collaborative networks.
The first day of the conference will be dedicated to presentations of feedback, needs and industrial innovations. The following days will focus on scientific updates. The 2017 conference will focus on topics that could build a bridhe between civilian and defence research & innovation in CBRNE countermeasures and explosive detection.
The 8th International Conference on Emerging Zoonoses in Kansas follows seven successful conferences. It will focus on Emerging & Transboundary Infectious Diseases.
In Manhattan, KS, United States from Sun, May 7 – Wed, May 10, 2017
Cali Conference, Colombia
The XIX International Congress for Tropical Medicine and Malaria (ICTMM 2016) in will be at held the Brisbane Convention & Exhibition Centre from Sunday 18th - Thursday 22nd September 2016.
IF Ebola consortium will be present.
Tofo Advanced study week: Ebola and Other filoviruses from 6th to 10th September 2015, in Inhambane, Mozambique.
For more information, visit the conference website http://www.ebola-conference.org/
- March 8-13: Gordon conferences in Ventura, CA,
- March 25-28: The 7th Filovirus Congress in Washington DC
- March 24-25: Institute of Medicine, Academy of Sciences in Washington DC
KICK OF MEETING IF EBOLA in LYON at Fabentech
Communication for the EU
IF EBOLA highlighted by the European Commission - The European Commission released in March 2015 an overview of its most innovative projects challenging Ebola. The IF EBOLA action is part of the five most innovative European projects.
IF EBOLA updated state of play- 10/08/2015
Resveratrol formulated with a natural deep eutectic solvent inhibits active matrix metalloprotease-9 in hormetic conditions - Scientific article on the optimisation of the RES capacity to inhibit aMMP-9 by using a new class of solvents, natural deep eutectic solvents (NADES) for a new RES formulation as compared with dimethyl-sulfoxide (DMSO).